Therapeutic Drug Monitoring of Gentamicin in Patients with Bronchopneumonia: Cost Considerations and Patient Outcomes | Zendy

Hisham Elhag Ahmed Abdelrahim | Zendy; Ab Fatah Ab Rahman | Zendy; Mohamad Izham Mohamed Ibrahim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapeutic Drug Monitoring of Gentamicin in Patients with Bronchopneumonia: Cost Considerations and Patient Outcomes

Author(s) -

Hisham Elhag Ahmed Abdelrahim,

Ab Fatah Ab Rahman,

Mohamad Izham Mohamed Ibrahim

Publication year - 2012

Publication title -

eurasian journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.337

H-Index - 13

eISSN - 1308-8742

pISSN - 1308-8734

DOI - 10.5152/eajm.2012.01

Subject(s) - medicine , gentamicin , nephrotoxicity , therapeutic drug monitoring , creatinine , intensive care medicine , emergency medicine , antibiotics , medical costs , pharmacotherapy , bronchopneumonia , total cost , pediatrics , drug , health care , pharmacology , toxicity , microbiology and biotechnology , economics , biology , microeconomics , economic growth

In Malaysia, therapeutic drug monitoring (TDM) service started in the late 1980s. Serum concentration measurements depend on commercially available drug assays, which are costly. In the present study, we attempted to document the impact of TDM service on cost and patient outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research